INBX - Inhibrx Biosciences Inc.
IEX Last Trade
14.52
0.610 4.201%
Share volume: 145,333
Last Updated: Fri 30 Aug 2024 09:59:57 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$13.91
0.61
4.39%
View ratios
Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
---|---|---|---|---|---|---|---|---|---|
Fiscal Quarter | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
Report Date | 2022-08-08 | 2022-11-07 | 2023-03-06 | 2023-05-08 | 2023-08-07 | 2023-11-09 | 2024-02-28 | 2024-05-09 | |
Total revenue | 711.000 K | 278.000 K | 274.000 K | 17.000 K | 30.000 K | 119.000 K | 1.634 M | 0.000 | |
Cost of revenue | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
Gross profit | 711.000 K | 278.000 K | 274.000 K | 17.000 K | 30.000 K | 119.000 K | 1.634 M | 0.000 | |
-60.90% | -1.44% | -93.80% | 76.47% | 296.67% | 1,273.11% | -100.00% | |||
Operating expenses | 35.308 M | 30.281 M | 35.774 M | 43.783 M | 41.369 M | 45.946 M | 89.923 M | 73.825 M | |
Selling general and admin | 5.402 M | 5.347 M | 5.323 M | 6.397 M | 7.263 M | 7.889 M | 7.832 M | 9.974 M | |
Research and development | 29.906 M | 24.934 M | 30.451 M | 37.386 M | 34.106 M | 38.057 M | 82.091 M | 63.851 M | |
Total expenses | 35.308 M | 30.281 M | 35.774 M | 43.783 M | 41.369 M | 45.946 M | 89.923 M | 73.825 M | |
-14.24% | 18.14% | 22.39% | -5.51% | 11.06% | 95.71% | -17.90% | |||
Operating income | -34.597 M | -30.003 M | -35.500 M | -43.766 M | -41.339 M | -45.827 M | -88.289 M | -73.825 M | |
Ebit | -34.597 M | -30.003 M | -35.500 M | -43.766 M | -41.339 M | -45.827 M | -88.289 M | -73.825 M | |
Pretax income | -37.728 M | -35.325 M | -40.916 M | -48.916 M | -47.047 M | -51.787 M | -91.974 M | -78.710 M | |
-6.37% | 15.83% | 19.55% | -3.82% | 10.08% | 77.60% | -14.42% | |||
Income tax | 4.000 K | 0.000 | -1.000 K | 0.000 | 5.000 K | 2.000 K | -4.000 K | 0.000 | |
Net income basic | -37.732 M | -35.325 M | -40.915 M | -48.916 M | -47.052 M | -51.789 M | -93.604 M | -78.710 M | |
6.38% | -15.82% | -19.56% | 3.81% | -10.07% | -80.74% | 15.91% | |||
Net income | -37.732 M | -35.325 M | -40.915 M | -48.916 M | -47.052 M | -51.789 M | -93.604 M | -78.710 M | |
6.38% | -15.82% | -19.56% | 3.81% | -10.07% | -80.74% | 15.91% |